Advertisement
Advertisement
XERS
Xeris Biopharma Holdings, Inc. Common Stock
8.74
USDSponsored
0.00
0.00%
Aug 25, 15:59 UTC -4
Closed
After-Market
8.67
-0.07
-0.80%
XERS Earnings Reports
Positive Surprise Ratio
XERS beat 18 of 33 last estimates.
55%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$103.38M
/$0.03
Implied change from Q2 26 (Revenue/ EPS)
+12.24%
/-116.67%
Implied change from Q3 25 (Revenue/ EPS)
+38.98%
/--
Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, XERS reported earnings of -0.18 USD per share (EPS) for Q2 26, missing the estimate of 0.00 USD, resulting in a -5394.12% surprise. Revenue reached 92.10 million, compared to an expected 92.03 million, with a 0.08% difference. The market reacted with a -9.25% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 103.38 million USD, implying an decrease of -116.67% EPS, and increase of 12.24% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.50
Actual
-$0.63
Surprise
-25.40%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
MediWound Ltd.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.77
Actual
-$0.77
Surprise
+0.89%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Nektar Therapeutics
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$2.02
Actual
-$1.23
Surprise
+39.24%
Karyopharm Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.30
Actual
-$2.31
Surprise
-78.16%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
FAQ
What were Xeris Biopharma Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of -$0.18, missing estimates by -5394.12%, and revenue of $92.10M, 0.08% above expectations.
How did the market react to Xeris Biopharma Holdings, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -9.25%, changed from $8.11 before the earnings release to $7.36 the day after.
When is Xeris Biopharma Holdings, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Xeris Biopharma Holdings, Inc. Common Stock's next earnings report?
Based on 6
analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of $0.03 and revenue of $103.38M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement